Business Wire

FDA Grants Marketing Authorization to Banyan Biomarkers for the First Diagnostic Blood Test for Traumatic Brain Injury

Del

Banyan Biomarkers, Inc., a pioneer in developing biomarkers for traumatic brain injury (TBI), today announced that the U.S. Food and Drug Administration (FDA) has granted the De Novo request for the commercialization of Banyan BTITM (Brain Trauma Indicator), an in vitro diagnostic blood test to aid in the evaluation of patients with suspected TBI, also known as concussion. The FDA, in keeping with its commitment to address urgent medical concern of brain injuries, reviewed the test under the Breakthrough Devices Program, which is intended to facilitate the development and expedite the review of innovative breakthrough technologies. Banyan BTI identifies two brain-specific protein biomarkers (Ubiquitin Carboxy-terminal Hydrolase-L1 or UCH-L1 and Glial Fibrilliary Acidic Protein or GFAP) that rapidly appear in the blood after a brain injury, providing objective information to assess patients with suspected mild TBI. The goal of the study was to identify patients with head trauma who could safely forego the need for a CT scan thereby avoiding unnecessary radiation to the brain and reduce costs of care.

“With extensive clinical research and scientific validation, Banyan BTI has shown that these two specific protein biomarkers, which are released from the brain and circulate in the blood after a brain injury, can provide objective data to healthcare providers when evaluating patients with a traumatic brain injury,” said Henry L. Nordhoff, Chairman and CEO of Banyan Biomarkers. “Receiving marketing authorization from the FDA for the first blood test for TBI is a significant milestone that will transform how brain injury is managed. We are honored to have as our partner, the U.S. Department of Defense and the U.S. Army Medical Research and Materiel Command, for supporting the research and development of a diagnostic test that now provides objective quantifiable information to physicians, to eliminate unnecessary CT scans, and guide patient care.”

Automobile accidents, falls, sports-related injuries, assaults, and, in the military, improvised explosive devices (IEDs) and combat wounds are common causes of TBI. The U.S. Center for Disease Control estimates there are more than 2.5 million emergency room visits in the United States as a result of head injuries and TBI is an economic burden of more than $76 billion annually on the healthcare system.1 Traumatic brain injury is the leading cause of disability and the number one cause of death for young adults.2

“The impact of traumatic brain injuries is felt within each branch of the service and throughout the Department of Defense, and were even considered the ‘signature wound’ from recent conflicts,” said Lt. Col. Kara Schmid, Project Manager for the Neurotrauma and Psychological Health Project Management Office for the U.S. Army Medical Materiel Development Activity. “Finding solutions for the diagnosis and evaluation of mild TBI has been a top priority for over a decade now. Obtaining FDA authorization for the first objective blood-based biomarkers of mild TBI is a huge success for the TBI community. This assay will provide a remarkable capability for the way we evaluate and care for our service members with TBI.”

Currently, the CT scan is routinely used to assist physicians in the evaluation of TBI. However, the use of CT scans is highly variable especially in the face of significant trauma with minimal symptoms. Lacking an approved biomarker to guide decision making, the default for physicians was to obtain a CT scan. More than 90 percent of patients presenting to the emergency department with mild TBI or concussion, have a negative CT scan.

“Brain biomarkers will change the practice of emergency care for mild TBI and will greatly assist a large number of patients. The impact will be improved medical care by reducing radiation exposure to the patient and improving efficiency in the emergency department,” stated Andy Jagoda, MD, Professor and Chair in the Department of Emergency Medicine at the Icahn School of Medicine at Mount Sinai.

The FDA granting of the De Novo request for Banyan BTI also creates a classification regulation for devices of this type and permits this diagnostic test to serve as a predicate device. The FDA granting was supported by a prospective multi-center pivotal study. The study called ALERT-TBI, enrolled 2,011 patients at 24 independent clinical sites in the United States and European Union and compared the test's results to head CT scans of patients presenting to emergency departments with suspected head injury. The study showed that Banyan BTI achieved high sensitivity and high NPV (negative predictive value) for ruling out the need for a head CT scan and provides objective data for healthcare providers to aid in the evaluation of patients with suspected TBI. The company is engaged in additional studies to determine if the biomarkers have applications in monitoring recovery after injury as well as their application in other degenerative conditions of the brain.

The development of Banyan BTI TM was supported by the U.S. Army Medical Research and Materiel Command under Contract No. W81XWH-10-C-0251. Any views, opinions, conclusions, and/or findings contained in this press release are those of Banyan Biomarkers, Inc. and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.

1 CDC  https://www.cdc.gov/traumaticbraininjury/severe.html
2 CDC www.cdc.gov/traumaticbraininjury/get_the_facts.html

About Banyan Biomarkers

Banyan Biomarkers, Inc. has developed the first blood test, Banyan BTI™, that can be used by physicians to objectively aid in the evaluation of patients with suspected traumatic brain injury (TBI), also known as concussions. Banyan BTI consists of two test kits (Banyan UCH-L1® Kit and Banyan GFAP® Kit) that measure two specific protein biomarkers that rapidly appear in the blood after a brain injury. To learn more about the Company and Banyan BTI, visit www.banyanbio.com.

Banyan Biomarkers, Banyan, Brain Trauma Indicator, BTI, Banyan UCH-L1, Banyan GFAP, and the brain and tree logos are the trademarks and copyrights of Banyan Biomarkers, Inc.

Contact information

Banyan Biomarkers, Inc.
Tony Grover
Vice President of Business Development
tgrover@banyanbio.com
+1 (760) 710-0423
or
Little Dog Communications Inc.
Jessica Yingling, Ph.D.
President
jessica@litldog.com
+1 (858) 344-8091

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Andersen Tax & Legal Launches in Egypt20.2.2018 14:30Pressemelding

The Andersen name launches in Egypt this week as Maher Milad Iskander and Co., an Egyptian tax and legal firm based in Cairo, formally adopts the name Andersen Tax & Legal. Maher Milad Iskander and Co. became a collaborating firm of Andersen Global in July of 2017 and is one of three that have become member firms and adopted the Andersen name thus far in 2018. Maher Milad Iskander, Managing Partner of Andersen Tax & Legal in Egypt, said, “Andersen Global’s strategy of focusing on outstanding tax and legal services will provide us with many advantages and will allow us to even better serve our cross-border clientele. We are looking forward to our continued work with the Andersen team and to seamlessly providing innovative and client-focused solutions on a global level through our colleagues around the world.” “Egypt is considered to be one of the highest growing markets in the world and our adoption of the Andersen name in Egypt has come at the perfect time,” added Global Chairman and A

New PubMatic Research Shows Private Marketplaces Drive Global Mobile Advertising Growth20.2.2018 14:00Pressemelding

PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today announced findings from its Q4 2017 Quarterly Mobile Index (QMI). The report, which identifies trends in mobile advertising, found that mobile private marketplaces (PMPs) monetized impression volume increased by 37 percent year-over-year (YOY) in Q4 2017, adding to a long growth streak for mobile PMPs now spanning eight consecutive quarters. The upswing for mobile PMPs is attributed to major marketers continuing to increase spend through programmatic channels. PMPs offer robust options for advertisers to gain access to premium inventory coupled with safeguards for ad fraud and brand risk, amid growing concerns about quality, viewability and transparency. For publishers, PMPs provide more control over their inventory and partnership with buyers. As a result, mobile PMP eCPMs globally in 2017 were priced at a 155 percent premium, compared to those paid for the average mobile open exchange imp

First Dedicated Esports Apparel Brand H4X.gg Unveils Its Debut Line of Performance Gear and Streetwear, Partners with ESL and DreamHack20.2.2018 14:00Pressemelding

Esports apparel and gear company Moniker, Inc. ("Moniker") has introduced the first esports lifestyle brand H4X.gg (pronounced “hacks”) with high quality performance wear and casual streetwear for esports athletes and fans. H4X.gg has partnered with ESL, the world’s largest esports company, and DreamHack, the world’s largest digital festival, to become the official apparel supplier of ESL One, Intel® Extreme Masters, DreamHack Open, DreamHack Masters and DreamLeague 2018, kicking off with ESL One in Katowice, Poland on February 24-25. "We are very happy to partner with the first dedicated esports apparel brand designed specifically for fans and players,” said Bernhard Mogk, SVP Global Sales & Business Development at ESL. “We’re incredibly excited to debut the line of performance gear at ESL One Katowice this month and roll out the entire line at future ESL events throughout 2018.” The H4X.gg line was developed by passionate gamers and esports industry veterans at BITKRAFT Esports Ventu

ETECSA Enhances Connectivity to the Rest of the World with SES Networks20.2.2018 14:00Pressemelding

Cubans and visitors to Cuba will have additional access to reliable and uninterrupted connectivity throughout the main island of Cuba as ETECSA, Cuba’s national telecommunications operator, signed a deal with SES Networks for satellite services, SES announced today. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180220005894/en/ ETECSA Enhances Connectivity to the Rest of the World with SES Networks (Photo: Business Wire) SES Networks will augment ETECSA’s existing terrestrial infrastructure with its high-performance fibre-like medium earth orbit (MEO) capacity and improve connectivity for end-customers of the Cuban operator. “By working with SES Networks, we are ensuring that our customers across the main island will have a new way to access high-performing Internet at all times through this innovative satellite system. Our collaboration with SES Networks highlights ETECSA’s mission of providing telecommunications services t

Proposals of the Supervisory Board to Be Submitted to the Annual General Shareholders' Meeting of Sartorius AG20.2.2018 14:00Pressemelding

At today’s meeting, the Supervisory Board of Sartorius AG, approved the Executive Board’s recommendation to submit a proposal to the Annual General Shareholders’ Meeting on April 5, 2018, to raise dividends to 0.51 euros per preference share and 0.50 euros per ordinary share. Prior-year dividends were 0.46 euros and 0.45 euros per preference share and per ordinary share, respectively. Therefore, the total amount disbursed under this proposal would increase by 11.0% to 34.5 million euros from 31.1 million euros a year earlier. In addition, the Supervisory Board will submit a proposal to the Annual General Shareholders’ Meeting to elect Dr. Guido Oelkers to the Supervisory Board as a representative of the shareholders. Guido Oelkers has already been a member of this board since November 2017. He was appointed by court order after Supervisory Board member Professor Arnold Picot, Ph.D., had passed away. Guido Oelkers, who was born in 1965 and holds a university degree in business administr

NMI Agrees to Acquire Creditcall to Expand EMV and Omnichannel Capabilities20.2.2018 13:04Pressemelding

NMI, a leading provider of payments enablement technology for independent sales organizations (ISOs), independent software vendors (ISVs), value-added resellers (VARs) and payment facilitators, today announced it has signed a definitive agreement to acquire Creditcall, an omnichannel payment gateway and EMV solutions provider. With offices in Bristol, England, and New York, and customers throughout many regions of the world, Creditcall will give NMI a global presence and access to new markets. This acquisition will continue to differentiate NMI from traditional payment gateway providers by further expanding its omnichannel and EMV capabilities, creating a one-of-a-kind payment gateway platform supporting all channels of commerce including retail, e-commerce, mobile and unattended. “The payment technology requirements of today’s merchants are more complex than ever—they need to accept and process payments in all sales channels and environments,” said Roy Banks, chief executive officer o